알레르기 치료제 시장 - 치료법별, 유형별, 투여 경로별, 유통 채널별, 세계 예측(2023-2032년)

The global allergy therapeutics market will showcase a 6.6% CAGR from 2023 to 2032. The increasing prevalence of allergies, including respiratory allergies like hay fever and food allergies, drives demand for effective treatments. Advancements in allergy diagnostics and immunotherapy techniques have improved treatment outcomes, driving business growth.

A growing awareness of allergies and their impact on health prompts individuals to seek medical intervention will bode well for the market expansion. Moreover, environmental factors like pollution and changing climate patterns lead to a higher incidence of allergies, opening a new scope for business growth.

Additionally, supportive healthcare policies, collaborative initiatives and the development of novel allergy therapeutics will further drive the market progress. Sanofi SA announced in July 2023 that it had agreed to acquire Qunol, a prominent U.S.-based brand specializing in the health and wellness industry.

The market is segregated based on treatment type, type, route of administration, distribution channel, and region.

Based on treatment type, the immunotherapy treatment segment will exhibit a 7% CAGR through 2032, driven by the increasing recognition of immunotherapy's effectiveness in addressing the root causes of allergies, reducing symptom severity, and providing long-term relief to patients, thus driving business growth for this treatment modality.

Based on type, the asthma segment will record 7.2% CAGR during 2023-2032, driven by factors such as increasing prevalence of asthma, expanding research in asthma therapeutics, and the development of advanced and more targeted treatments for asthma patients, fueling growth in the segment.

The intranasal route of administration segment will depict a 6.8% CAGR throughout the analysis period. The convenience and patient preference for non-invasive treatments, the effectiveness of intranasal delivery in managing allergic symptoms, and continuous innovation in intranasal allergy therapies will drive growth in the segment.

Regionally, the Asia Pacific allergy therapeutics industry is estimated to grow at a 7% CAGR during the analysis timeline, driven by the region's increasing prevalence of allergies and rising healthcare infrastructure. Moreover, the expanding patient awareness and growing demand for effective allergy treatments will foster business growth in the region.

Table of Contents

Chapter 1 Delivery Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Allergy therapeutics industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Treatment type trends
  • 2.1.4 Type trends
  • 2.1.5 Route of administration trends
  • 2.1.6 Distribution channel trends

Chapter 3 Allergy Therapeutics Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of allergic conditions
    • 3.2.1.2 Increased awareness about allergies and their impact on health
    • 3.2.1.3 Rising advancements in biotechnology, genomics, and personalized medicine
    • 3.2.1.4 Increasing demand for new and improved treatment options
    • 3.2.1.5 Increasing healthcare expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Lack of standardization in allergen extracts
    • 3.2.2.3 Undiagnosed or underdiagnosed cases due to a lack of awareness, mild symptoms, or limited access to healthcare
• 3.3 Growth potential analysis
  • 3.3.1 By treatment type
  • 3.3.2 By type
  • 3.3.3 By route of adminstration
  • 3.3.4 By distribution channel
• 3.4 COVID- 19 impact analysis
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Company market share analysis, 2022
• 4.4 Competitive analysis of major market players, 2022
• 4.5 Competitive positioning matrix, 2022
• 4.6 Strategic outlook matrix, 2022

Chapter 5 Allergy Therapeutics Market Size and Forecast, By Treatment type (USD Million)

• 5.1 Key trends, by treatment type
• 5.2 Anti-allergy drugs
  • 5.2.1 Antihistamines
  • 5.2.2 Corticosteroids
  • 5.2.3 Decongestants
  • 5.2.4 Other drugs
• 5.3 Immunotherapy
  • 5.3.1 Sub-cutaneous immunotherapy (SCIT)
  • 5.3.2 Sub-lingual immunotherapy (SLIT)

Chapter 6 Allergy Therapeutics Market Size and Forecast, By Type (USD Million)

• 6.1 Key trends, by type
• 6.2 Eye allergy
• 6.3 Asthma
• 6.4 Skin allergy
• 6.5 Food allergies
• 6.6 Rhinitis
• 6.7 Other allergy types

Chapter 7 Allergy Therapeutics Market Size and Forecast, By Route of administration (USD Million)

• 7.1 Key trends, by route of administration
• 7.2 Oral
• 7.3 Inhalers
• 7.4 Intranasal
• 7.5 Other routes of administration

Chapter 8 Allergy Therapeutics Market Size and Forecast, By Distribution Channel (USD Million)

• 8.1 Key trends, by distribution channel
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Allergy Therapeutics Market Size and Forecast, By Region (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Allergopharma
• 10.2 Danaher
• 10.3 AbbVie, Inc.
• 10.4 Allergy Therapeutics plc
• 10.5 Sanofi SA
• 10.6 Pfizer, Inc.
• 10.7 Teva Pharmaceutical Industries Ltd.
• 10.8 GlaxoSmithKline plc
• 10.9 F. Hoffmann-La Roche Ltd.
• 10.10 Merck & Co., Inc.